1. Shah K, Tankersley W, Mekala H. Kratom: an emerging issue and need for regulations in the United States. Prim Care Companion CNS Disord. 2021;23(1):26032.
2. National Archives Federal Register. Withdrawal of notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into schedule I 2016 [Available from: https://www.federalregister.gov/documents/2016/10/13/2016-24659/withdrawal-of-notice-of-intent-to-temporarily-place-mitragynine-and-7-hydroxymitragynine-into. Accessed Oct 2023.
3. Henningfield JE, Wang DW, Huestis MA. Kratom abuse potential 2021: an updated eight factor analysis. Front Pharmacol. 2021;2022:3579.
4. Prozialeck WC, Avery BA, Boyer EW, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70–7.
5. Tavakoli HR, Buchholz AC, Kabir IK, et al. Kratom: a new product in an expanding substance abuse market. Fed Pract. 2016;33(11):32.